Domain and Merck Serono in Parkinson's alliance
This article was originally published in Scrip
Domain Therapeutics of France has signed an exclusive development and licensing agreement with Merck Serono (Merck KgaA) targeting Parkinson's disease and other neurodegenerative diseases.
You may also be interested in...
Prexton Therapeutics has the only mGluR4-targeting drug candidate in clinical testing, after a number of big pharma dropped preclinical programs. The company has just secured €29m to fund two Phase II trials.
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.